Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Q/C TECHNOLOGIES, INC. Regulatory Filings 2020

Mar 23, 2020

35313_rns_2020-03-23_e91049a7-5b18-4308-9674-aca36199e828.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

CORRESP 1 filename1.htm

Akers Biosciences, Inc.

201 Grove Road

Thorofare, New Jersey 08086

March 23, 2020

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Securities and Exchange Commission

Washington, D.C. 20549

Attention: Paul Fischer

Re:
Registration
Statement on Form S-3, originally filed on November 1, 2019
File
No. 333-234449 (the “ Registration Statement ”)
Request
for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “ Commission ”) under the Securities Act of 1933, as amended, Akers Biosciences, Inc. (the “ Company ”) hereby respectfully requests acceleration of the effective date of the Registration Statement so that it may become effective at 4:00 p.m., Eastern Time, on March 24, 2020, or as soon thereafter as practicable.

Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.

| Very

truly yours,
AKERS
BIOSCIENCES, INC.
By: /s/
Christopher Schreiber
Christopher
Schreiber Executive Chairman of the Board of Directors and Director

cc: Rick A. Werner, Esq., Haynes and Boone, LLP

Field: Page; Sequence: 1

Field: /Page